TECH
Bio-Techne Corp
$
53.600
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
54.380
Open
54.330
VWAP
53.75
Vol
1.31M
Mkt Cap
8.40B
Low
53.385
Amount
70.19M
EV/EBITDA(TTM)
36.94
Total Shares
157.58M
EV
8.59B
EV/OCF(TTM)
29.86
P/S(TTM)
6.99
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q2
FY2026Q1
324.66M
+2.68%
0.570
+1.81%
300.69M
+1.23%
0.461
+9.86%
293.06M
+1.24%
0.424
+1.01%
Estimates Revision
The market is revising Downward the revenue expectations for Bio-Techne Corporation (TECH) for FY2026, with the revenue forecasts being adjusted by -4.09% over the past three months. During the same period, the stock price has changed by 8.77%.
Revenue Estimates for FY2026
Revise Downward
-4.09%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
-3.55%
In Past 3 Month
Stock Price
Go Up
+8.77%
In Past 3 Month
13 Analyst Rating
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 65.00 USD with a low forecast of 58.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 53.600
Low
58.00
Averages
65.00
High
75.00
Current: 53.600
Low
58.00
Averages
65.00
High
75.00
Stephens
Steven Etoch
initiated
$65
2025-07-21
Reason
Stephens
Steven Etoch
Price Target
$65
2025-07-21
initiated
Reason
Stephens analyst Steven Etoch resumed coverage of Bio-Techne with an Overweight rating and $65 price target. The firm says the company through acquisitions has a "high-quality" recurring-revenue life science tools platform. The shares are down 27% year-to-date, creating Bio-Techne's lowest valuation since 2017, on "transitory headwinds" tied to government and academic funding concerns, the analyst tells investors in a research note. Stephens is constructive on the company's exposure to secular growth themes in diagnostics and cell and gene therapy.
TD Cowen
NULL
to
Buy
initiated
$65
2025-07-09
Reason
TD Cowen
Price Target
$65
2025-07-09
initiated
NULL
to
Buy
Reason
TD Cowen initiated coverage of Bio-Techne with a Buy rating and $65 price target. The pullback and multiple de-rating look overdone, even though macro risks have weighed on shares, the analyst tells investors in a research note. The current valuation doesn't reflect the strong organic growth and margin opportunity where Bio-Techne addresses several of the highest growth areas in Tools with strong product offerings, TD Cowen adds.
Wells Fargo
Brandon Couillard
Overweight
initiated
$59
2025-05-30
Reason
Wells Fargo
Brandon Couillard
Price Target
$59
2025-05-30
initiated
Overweight
Reason
Wells Fargo analyst Brandon Couillard initiated coverage of Bio-Techne with an Overweight rating and $59 price target. The firm believes Bio-Techne's "unique" portfolio is well positioned to deliver sustained above-average organic revenue and earnings growth. The company is exposed to high-growth verticals, such as good manufacturing practice reagents, proteomic instruments, spatial biology and precision diagnostics, the analyst tells investors in a research note. Wells believes the recent pullback in the shares offers a compelling entry point.
Argus
Buy
downgrade
$90 -> $65
2025-05-30
Reason
Argus
Price Target
$90 -> $65
2025-05-30
downgrade
Buy
Reason
Argus lowered the firm's price target on Bio-Techne to $65 from $90 but keeps a Buy rating on the shares. Bio-Techne's endmarkets have improved, but it now faces multiple headwinds in the form of trade tariffs and cuts in funding to academic and government customers, the analyst tells investors in a research note. Given the changing dynamics for tariffs and NIH funding however, these headwinds may well be temporary and the improving end markets may be more sustainable, the firm added.
UBS
Buy
downgrade
$95 -> $70
2025-05-09
Reason
UBS
Price Target
$95 -> $70
2025-05-09
downgrade
Buy
Reason
UBS lowered the firm's price target on Bio-Techne to $70 from $95 and keeps a Buy rating on the shares. Bio-Techne's update reflects heightened market challenges, but it "could have been worse," the analyst tells investors in a research note.
Stifel
Hold
downgrade
$75 -> $60
2025-05-08
Reason
Stifel
Price Target
$75 -> $60
2025-05-08
downgrade
Hold
Reason
Stifel lowered the firm's price target on Bio-Techne to $60 from $75 and keeps a Hold rating on the shares. Growth is expected to step down to the low-single digit range in fiscal Q4, notes the analyst, who sees Bio-Techne as "somewhat caught between trying to lower expectations in a way that derisks the outlook while still signaling growth possibilities that can yield top-line differentiation."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bio-Techne Corp (TECH.O) is 26.66, compared to its 5-year average forward P/E of 43.04. For a more detailed relative valuation and DCF analysis to assess Bio-Techne Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
43.04
Current PE
26.66
Overvalued PE
53.36
Undervalued PE
32.73
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
30.23
Current EV/EBITDA
19.69
Overvalued EV/EBITDA
37.01
Undervalued EV/EBITDA
23.45
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
11.40
Current PS
6.76
Overvalued PS
14.50
Undervalued PS
8.30
Financials
Annual
Quarterly
FY2025Q4
YoY :
+3.55%
316.96M
Total Revenue
FY2025Q4
YoY :
-133.24%
-23.86M
Operating Profit
FY2025Q4
YoY :
-143.55%
-17.68M
Net Income after Tax
FY2025Q4
YoY :
-144.00%
-0.11
EPS - Diluted
FY2025Q4
YoY :
+62.23%
93.31M
Free Cash Flow
FY2025Q4
YoY :
-5.58%
62.72
Gross Profit Margin - %
FY2025Q4
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q4
YoY :
-142.08%
-5.58
Net Margin - %
FY2025Q4
YoY :
-59.23%
3.16
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
63.7K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
1.2M
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 308.81% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
4.5K
Volume
1
6-9
Months
1.1M
Volume
8
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
1.6M
Volume
Months
6-9
2
397.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
32.0K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
4
32.0K
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
63.7K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
1.2M
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TECH News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
07:04:34
Bio-Techne reports Q4 adjusted EPS 53c, consensus 50c
2025-08-05 (ET)
2025-08-05
16:40:19
Bio-Techne to divest Exosome Diagnostics business to Mdxhealth
2025-07-15 (ET)
2025-07-15
07:04:27
Bio-Techne and Spear Bio partner for ultrasensitive biomarker detection
Sign Up For More Events
Sign Up For More Events
News
3.5
08-14PRnewswireScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory
4.0
08-07BenzingaRBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $61
9.5
08-06NASDAQ.COMBio-Techne (TECH) Q4 EPS Rises 8.2%
Sign Up For More News
People Also Watch
TXRH
Texas Roadhouse Inc
172.840
USD
-0.04%
HST
Host Hotels & Resorts Inc
15.720
USD
-1.63%
OVV
Ovintiv Inc
39.400
USD
-1.10%
CPT
Camden Property Trust
106.820
USD
+0.75%
AAL
American Airlines Group Inc
13.170
USD
+2.73%
RTO
Rentokil Initial PLC
24.530
USD
-2.43%
NCLH
Norwegian Cruise Line Holdings Ltd
24.300
USD
-0.25%
NVT
nVent Electric PLC
88.010
USD
-1.99%
RKLB
Rocket Lab Corp
44.270
USD
+3.41%
CIEN
Ciena Corp
90.870
USD
-0.60%
FAQ
What is Bio-Techne Corp (TECH) stock price today?
The current price of TECH is 53.6 USD — it has decreased -0.26 % in the last trading day.
What is Bio-Techne Corp (TECH)'s business?
What is the price predicton of TECH Stock?
What is Bio-Techne Corp (TECH)'s revenue for the last quarter?
What is Bio-Techne Corp (TECH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bio-Techne Corp (TECH)'s fundamentals?
How many employees does Bio-Techne Corp (TECH). have?